ESMO TAT 2023 | Optimizing drug dosage in targeted therapies

Igor Vivanco, PhD, King’s College London, London, UK, discusses validating targets in patients with brain tumors to ensure an effective response is elicited. For example, the concentration of EGFR inhibitors in in vitro brain tumors conclusions can be assessed in order to draw conclusions on clinical responses. The idea that oncogene addiction in glioblastoma does not exist is discouraged and the report of exceptional responses using targeted agents as evidence of oncogene addiction in these patients is highlighted. Professor Vivanco identifies the need for a different source of target identification, moving away from sequencing methods. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.